How a Futurist Sees Healthcare Being Delivered!

 

In a recent episode of the “Healthcare Rethink” podcast by FinThrive, host Brian Urban explored the future of healthcare with Trond Arne Undheim, a leading Futurist and Research scholar in Global Systemic Risk, Innovation, and Policy. Undheim, author of “Health Tech: Rebooting Society Software, Hardware, and Mindset,” shared his vision of a healthcare system transformed by emerging technologies and innovative business models.

Undheim’s futurist outlook emphasized the revolutionary potential of generative AI and remote patient monitoring to democratize healthcare access, particularly in underserved regions. By leveraging these technologies, healthcare providers can offer remote consultations and continuous monitoring, bridging gaps in care and ensuring that even those in rural or low-income areas receive quality medical attention. This shift improves patient outcomes and addresses longstanding disparities in healthcare access.

A significant part of this transformation involves redefining the roles of healthcare professionals. Undheim envisions a future where AI and advanced technologies support and enhance the capabilities of nurses and other healthcare workers, enabling them to take on more significant responsibilities. This evolution could alleviate the burden on doctors, optimize resource use, and improve the efficiency of healthcare delivery. However, it also requires a thoughtful implementation approach to maintain high care standards.

Undheim argues that a systemic overhaul of the healthcare industry is essential for these technological advancements to reach their full potential. This overhaul includes updating regulatory frameworks, rethinking economic incentives, and fostering a culture of innovation. With such comprehensive reforms, the healthcare sector can stay caught up and fully benefit from the advancements that could transform it into a more effective and equitable system.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…